For the third straight quarter in a row, OmniComm Systems, a leader in integrated electronic data capture solutions for clinical trials, is reporting another landmark quarter for new business. The company has surpassed its previous best quarter and signed contracts through the first two quarters of 2008 totaling almost $12 million, which surpass all of the revenues brought in from last year’s signed contracts.

During the second quarter, OmniComm signed a long-term guaranteed contract with a major biotechnology company which helped to boost the company’s financials. They have also continued to increase their customer base by adding seven new clients to their customer list, and continue to see recurring business from their existing loyal customers, who have added five more trials. Finally, they have added six new partners to their very successful Preferred Partnership Programs.

“I couldn’t be happier with the current momentum and speed in which we continue to

Shares of Discovery Labs (DSCO) have been drifting lower in recent trading and now are at the $1.55 level, which is a nice entry point for a long position for speculative biotech investors. Since meeting with the FDA in mid-June, DSCO has trended lower on investor disappointment that the Company would delay its response to the most recent approvable ruling for Surfaxin until September. However, the Company still expects a Class I review (60 days), which could result in approval for Surfaxin by late November or early December without the need for additonal clinical trials. Summer is typically a slow time for biotech trading and provides a good time to accumulate shares ahead of a Fall catalyst.